FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular, to a method for producing a multispecific IgG1-type antibody, wherein the amino acid residues at positions 356 and 439 in accordance with the EU numbering at the CH3 sites have a charge sufficient to achieve improved dissociation of the Fc sites and/or control of association thereof by using charge repulsion.
EFFECT: invention is effective in producing therapeutic and preventive agents, including those for treatment of cancer.
3 cl, 12 dwg, 12 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING A POLYPEPTIDE HETEROMULTITERS | 2014 |
|
RU2730594C2 |
| ANTI-CD137 ANTIGEN-BINDING MOLECULES AND USE THEREOF | 2019 |
|
RU2829536C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
| METHOD OF PRODUCING VARIANTS OF FCYRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2820161C1 |
| VERSIONS OF FCΓRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2729831C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2017 |
|
RU2827545C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
